Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex

Phase 1pidnarulexNeutral

AI Analysis

Summary

Senhwa Biosciences has completed patient enrolment in its Phase Ib expansion trial of pidnarulex as a monotherapy for advanced solid tumours with BRCA1/2 or PALB2 mutations.

Clinical Trial Data

Phase

Outcome Details

patient enrolment completed

Importance:4/10

Sentiment:

0.00

oncologyBRCA1/2PALB2solid tumoursPhase Ib

Related Companies

$SLDB $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 26, 2026 8:49 AM

Read Original